320
Participants
Start Date
June 9, 2022
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
MRTX1719
"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
RECRUITING
David H Koch, Memorial Sloan Kettering Cancer Center, New York
RECRUITING
New york cancer and blood specialists - Oncology, Port Jefferson Station
RECRUITING
New york cancer and blood specialists - Oncology, Port Jefferson Station
RECRUITING
Virginia Cancer Specialists, PC, Fairfax
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Mayo Clinic, Jacksonville
RECRUITING
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
RECRUITING
Cancer and Hematology Centers of Western Michigan, Norton Shores
RECRUITING
Medical College of Wisconsin - Froedtert Hospital, Milwaukee
RECRUITING
Mayo Clinic, Rochester
WITHDRAWN
Local Institution - 124, Chicago
RECRUITING
Ut Southwestern, Dallas
RECRUITING
Texas Oncology - DFW, Fort Worth
COMPLETED
Local Institution - 108, Houston
RECRUITING
MDACC, Houston
RECRUITING
South Texas Accelerated Research Therapeutics, San Antonio
RECRUITING
Texas Oncology, P.A. - Oncology, Tyler
RECRUITING
Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree
WITHDRAWN
Local Institution - 134, Seattle
RECRUITING
Mayo Clinic, Phoenix
RECRUITING
Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver
RECRUITING
Dana-Farber Cancer Institute, Brookline
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Vanderbilt - Ingram Cancer Center, Nashville
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY